IDEAS home Printed from
   My bibliography  Save this paper

Cost-sharing and pharmaceutical utilisation in Russia: evidence from a household survey


  • Andrew Street

    () (Centre for Health Economics, The University of York)

  • Andrew Jones
  • Aya Furuta


The Russian pharmaceutical sector is currently undergoing reform of the procurement, distribution and financing of medical drugs. The political imperatives underpinning these changes are wide ranging, and include the desire to protect local industry while benefiting from higher quality or less expensive imports. It is also felt that there should be some form of cost sharing between consumers and the government, in the belief that this will deliver socially optimal usage of pharmaceuticals and help control disease. Routine official statistics on drug use in the Russian Federation are unavailable, and data collected prior to the collapse of the Soviet Union can no longer be used for predictive purposes. The former centralised health system, offering universal free care, has disintegrated and the local production and distribution of pharmaceuticals has all but collapsed. While attempts are made to preserve the principle of free universal access, in reality patients are having to pay an increasing proportion of medical and pharmaceutical costs, and are facing greater problems in securing medication. Hospitals rely increasingly on humanitarian aid for supplies of drugs, and patients are often forced to secure a full range of medication, including antibiotics and anaesthetics, prior to hospital admission. Traditionally certain categories of the population have been exempted from pharmaceutical charges. Exemption categories are now no longer standard across the Federation: the universality of exemption status proclaimed in December 1992 (Decree 970) was largely overturned in July 1994 (Decree 890) which gave oblasts (regional governments) considerable autonomy in deciding eligibility for exemption, the list of exempt items, and reimbursement levels. The introduction of Compulsory Health Insurance has further eroded the principles of solidarity. Nor are entitlements widely publicised, particularly if oblast governments cannot afford to honour them and, even if patients are aware of their exemption status, claiming the reimbursement for which they are eligible is problematic. The household survey used in this study suggests that many are not aware of their exemption status and some are denied the right to purchase preparations against an exemption certificate. Future government policy is likely to be directed at designing an equitable and affordable system of cost-sharing with patients, and this paper aims to assist this process. The following section outlines the economic theory underpinning co-payments, including discussion of the impact of cost-sharing on consumer decisions and government revenues. The remainder of the paper addresses the impact of exemption status, and other socio-economic variables, on pharmaceutical use in Russia. Estimates are derived from a survey of over 4,000 households conducted in Russia in 1996. The data and sample are described in Section III. Separate models for the utilisation of prescriptions and for the overall level of household expenditure on pharmaceuticals are presented in Section IV. The analysis generates price and income elasticities of the demand for pharmaceuticals, which can be used to calculate the impact of different levels of co-payment. The policy implications of this are drawn out in Section V, while concluding comments are made in Section VI.

Suggested Citation

  • Andrew Street & Andrew Jones & Aya Furuta, 1997. "Cost-sharing and pharmaceutical utilisation in Russia: evidence from a household survey," Working Papers 155chedp, Centre for Health Economics, University of York.
  • Handle: RePEc:chy:respap:155chedp

    Download full text from publisher

    File URL:
    File Function: First version, 1997
    Download Restriction: no

    References listed on IDEAS

    1. Manning, Willard G, et al, 1987. "Health Insurance and the Demand for Medical Care: Evidence from a Randomized Experiment," American Economic Review, American Economic Association, vol. 77(3), pages 251-277, June.
    2. Vuong, Quang H, 1989. "Likelihood Ratio Tests for Model Selection and Non-nested Hypotheses," Econometrica, Econometric Society, vol. 57(2), pages 307-333, March.
    3. Wagstaff, Adam, 1986. "The demand for health : Some new empirical evidence," Journal of Health Economics, Elsevier, vol. 5(3), pages 195-233, September.
    4. Michael Grossman, 1972. "The Demand for Health: A Theoretical and Empirical Investigation," NBER Books, National Bureau of Economic Research, Inc, number gros72-1, January.
    5. William H. Greene, 1994. "Accounting for Excess Zeros and Sample Selection in Poisson and Negative Binomial Regression Models," Working Papers 94-10, New York University, Leonard N. Stern School of Business, Department of Economics.
    6. Leibowitz, Arleen & Manning, Willard G. & Newhouse, Joseph P., 1985. "The demand for prescription drugs as a function of cost-sharing," Social Science & Medicine, Elsevier, vol. 21(10), pages 1063-1069, January.
    7. O'Brien, Bernie, 1989. "The effect of patient charges on the utilisation of prescription medicines," Journal of Health Economics, Elsevier, vol. 8(1), pages 109-132, March.
    Full references (including those not matched with items on IDEAS)


    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.

    Cited by:

    1. Andrew Street & Jane Haycock, 1999. "The economic consequences of reorganizing hospital services in Bishkek, Kyrgyzstan," Health Economics, John Wiley & Sons, Ltd., vol. 8(1), pages 53-64.
    2. Pavlova, Milena & Groot, Wim & van Merode, Godefridus, 2002. "Public attitudes towards patient payments in Bulgarian public health care sector: results of a household survey," Health Policy, Elsevier, vol. 59(1), pages 1-24, January.

    More about this item


    Russia; pharmaceuticals;


    Access and download statistics


    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:chy:respap:155chedp. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Gill Forder). General contact details of provider: .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.